Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

Diabetes and Metabolism

Volumn 39, Issue 6, 2013, Pages 485-496

  Owens, D R ^a   Monnier, L ^b   Bolli, G B ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

GLP 1 receptor agonists; Incretin; Prandial; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; BIPHASIC INSULIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA;

CONCENTRATION (PARAMETERS); DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; STOMACH EMPTYING; TACHYPHYLAXIS;

AGONISTES DES RÉCEPTEURS DU GLP-1; DIABÈTE SUCRÉ DE TYPE 2; EFFET PRANDIAL; GLP-1 RECEPTOR AGONISTS; INCRETIN; INCRÉTINE; PRANDIAL; TYPE 2 DIABETES MELLITUS;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 84887571521     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.09.004     Document Type: Review

References (66)

1. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
2. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
3. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
4. Christensen M., Knop F.K., Vilsboll T., Holst J.J. Lixisenatide for type 2 diabetes mellitus. Expert Opin Invest Drugs 2011, 20:549-557.
5. Nauck M.A., Petrie J.R., Sesti G., Mannucci E., Courreges J.P., Atkin S., et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes (T2D). Presented at the 48th EASD Annual Meeting 2012.
6. Werner U., Haschke G., Herling A.W., Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010, 164:58-64.
7. Kolterman O.G., Kim D.D., Shen L., Ruggles J.A., Nielsen L.L., Fineman M.S., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62(2):173-181.
8. Thorkildsen C., Neve S., Larsen B.D., Meier E., Petersen J.S. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003, 307:490-496.
9. Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
10. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43:1664-1669.
11. Elbrond B., Jakobsen G., Larsen S., Agerso H., Jensen L.B., Rolan P., et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25:1398-1404.
12. Neumiller J.J. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011, 33:528-576.
13. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
14. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
15. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
16. Moretto T.J., Milton D.R., Ridge T.D., Macconell L.A., Okerson T., Wolka A.M., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460.
17. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
18. DeFronzo R.A., Triplitt C., Qu Y., Lewis M.S., Maggs D., Glass L.C. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010, 33:951-957.
19. Derosa G., Maffioli P., Salvadeo S.A., Ferrari I., Ragonesi P.D., Querci F., et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010, 12:233-240.
20. Derosa G., Putignano P., Bossi A.C., Bonaventura A., Querci F., Franzetti I.G., et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011, 666:251-256.
21. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
22. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
23. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
24. Davies M.J., Donnelly R., Barnett A.H., Jones S., Nicolay C., Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009, 11:1153-1162.
25. Zinman B., Hoogwerf B.J., Duran Garcia S., Milton D.R., Giaconia J.M., Kim D.D., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146:477-485.
26. Buse J.B., Bergenstal R.M., Glass L.C., Heilmann C.R., Lewis M.S., Kwan A.Y., et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
27. Blevins T., Pullman J., Malloy J., Yan P., Taylor K., Schulteis C., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011, 96:1301-1310.
28. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
29. Bergenstal R.M., Wysham C., Macconell L., Malloy J., Walsh B., Yan P., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
30. Russell-Jones D., Cuddihy R.M., Hanefeld M., Kumar A., Gonzalez J.G., Chan M., et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012, 35:252-258.
31. Buse J.B., Nauck M.A., Forst T. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2012, 381:117-124.
32. Diamant M., Van Gaal L., Stranks S., Northrup J., Cao D., Taylor K., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375:2234-2243.
33. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R.A., Hu P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265.
34. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
35. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
36. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
37. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
38. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
39. Marre M., Shaw J., Brandle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
40. Ahren B., Leguizamo Dimas A., Miossec P., Saubadu S., Aronson R. Efficacy and safety of lixisenatide once-daily morning and evening injections vs placebo in T2DM inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013, 36:2543-2550.
41. Riddle M.C., Aronson R., Home P.D. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison study (GetGoal-L). Diabetes Care 2013, 36:2489-2496.
42. Bolli G.B., Munteanu M., Dotsenko S., Niemoeller E., Boka G., Hanefeld M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1). Diabet Med 2013, [In print].
43. Fonseca V.A., Alvarado-Ruiz R., Raccah D., Boka G., Miossec P., Gerich J.E., et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012, 35:1225-1231.
44. Pinget M., Goldenberg R., Niemoeller E., Muehlen-Bartmer I., Guo H., Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013, 10.1111/dom.12121.
45. Ratner R.E., Hanefeld M., Shamanna P. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea±metformin (GetGoal-S). Diabetologia 2011, 54:S317.
46. Riddle M., Forst T., Aronson R., Sauque-Reyna L., Souhami E., Silvestre L., et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013, 36:2497-2503.
47. Rosenstock J., Koranyi R.D.L. Efficacy and safety of lixisenatide once-daily versus exenatide twice-daily in patients with type 2 diabetes insufficiently controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2012, (10):2945-2951.
48. Seino Y., Min K.W., Niemoeller E., Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012, 14:910-917. on behalf of the EFCG-LASI.
49. Pan C.Y., Niemoeller E. Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin±sulfonylurea (SU): GetGoal-M Asia 2012, On behalf of the GetGoal-M Asia study investigators, [November 24-27].
50. Seino Y., Niemoeller E., Sakaki T. Long-term safety of once-daily (QD) lixisenatide in Japanese patients with type 2 diabetes mellitus (T2DM): GetGoal-Mono-Japan 2012, On behalf of the GetGoal Mono study group, [November 24-27].
51. Lorenz M., Pfeiffer C., Steinsträßer A., Becker R., Rütten H., Ruus P., et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes-Relationship to postprandial glycemia. Regul Pept 2013, 185:1-8.
52. Fonseca V.L., Ahren B., Chow F., Gross J., Ratner R., Johnson S., et al. Once weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar glycaemic control with weight loss and less hypoglycaemia. Presented at the 48th EASD annual meeting 2012, [Abstract 581].
53. Pratley R.E., Barnett A.H., Feinglos M.N. Efficacy and safety of once-weekly (QW) albiglutide vs once-daily (QD) liraglutide in type 2 diabetes (T2D) inadequately controlled on oral agents: Harmony 7 trial. Presented at the 72nd ADA Scientific Sessions 2012, [Abstract 945-P].
54. Taylor K., Gurney K., Han J., Pencek R., Walsh B., Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011, 11:9.
55. Kapitza C., Forst T., Coester H., Poitiers F., Ruus P., Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled with metformin. Diabetes Obes Metab 2013, 15(7):642-649.
56. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
57. Nauck M.A., Kemmeries G., Holst J.J., Meier J.J. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011, 60:1561-1565.
58. The DECODE Study Group, European Diabetes Epidemiology Group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354:617-621.
59. Petersen A., Christensen M. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndrome Obes 2013, 6:217-231.
60. 1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011, 34:2508-2514.
61. Peter R., Dunseath G., Luzio S.D., Owens D.R. Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes. Diabet Metab 2013, 10.1016/j.diabet.2013.07.001.
62. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
63. Ratner R.E., Rosenstock J., Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010, 27:1024-1032. Investigators DRIS.
64. Fineman M.S., Cirincione B.B., Maggs D., Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012, 14:675-688.
65. Berg J.K., Shenouda S.K., Heilmann C.R., Gray A.L., Holcombe J.H. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011, 13:982-989.
66. Arnolds S., Dellweg S., Clair J., Dain M.P., Nauck M.A., Rave K., et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010, 33:1509-1515.